Arrowhead Research ARWR today announced that it has signed a research collaboration and
license agreement with Shire SHPG, to develop and commercialize targeted
peptide-drug conjugates (PDCs) by utilizing Arrowhead's human-derived
Homing Peptide platform and Shire's therapeutic payloads. Arrowhead will
receive research funding and could be eligible for development,
regulatory, and commercialization milestone payments of up to $32.8
million for each development candidate, plus additional milestone
payments for a second indication, and royalties on worldwide sales.
Additional financial terms of the agreement were not disclosed.
“Shire's expertise in developing innovative medicines for rare diseases
makes them an ideal partner for Arrowhead as we advance our platform of
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in